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Abstract
Upregulation of CCR2 chemokine receptor expression by dorsal root ganglion (DRG) neurons is an
important process in the development and maintenance of neuropathic pain. CCR2 is not expressed
by DRG neurons under normal conditions but is upregulated in several animal models of neuropathic
pain where its signaling is excitatory. However, the molecular mechanisms underlying neuronal
upregulation of CCR2 have not been investigated. We examined the promoter region of the CCR2
gene and found that a binding site for the nuclear factor of activated T-cells (NFAT) was conserved
among species. The NFAT element was functional since the CCR2 promoter was activated by a
constitutively active form of calcineurin A, whereas a point mutation in the NFAT binding site
abrogated it. Activation of the NFAT pathway in the DRG neuronal cell line F11 increased CCR2
promoter activity and induced CCR2 transcription. Moreover, depolarization of cultured DRG
neurons induced de novo synthesis of CCR2 mRNA, which was blocked by the calcineurin inhibitors
cyclosporin A and FK506. These data indicate that CCR2 is a target of the NFAT pathway and suggest
that tonic excitation of DRG neurons in association with chronic pain may lead to neuronal CCR2
upregulation via activation of the NFAT pathway.
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Introduction
Long-term changes in the profile of gene transcription in dorsal root ganglion (DRG) cells and
in the central nervous system (CNS) are believed to underlie the heightened pain sensitivity
observed in neuropathic pain states. Many genes are differentially regulated by DRG neurons
and glia in different animal models of chronic pain, suggesting multiple signaling pathways
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may contribute to this process (Basbaum and Woolf, 1999; Ji and Strichartz, 2004; Mogil et
al., 2000). However, the mechanism by which such changes occur is poorly understood.
Expression of the CCR2 chemokine receptor has been found to be upregulated by DRG neurons
in association with several animal models of neuropathic pain (Bhangoo et al., 2006; White et
al., 2005b). Under normal circumstances neither CCR2 nor its ligand MCP-1/CCL2 are
expressed by DRG neurons, whereas their expression is upregulated under pathological
conditions (Bhangoo et al., 2006; Sun et al., 2006; White et al., 2005b). Importantly, DRG
neurons from animals exhibiting neuropathic pain are strongly excited by the application of
MCP-1, whereas neurons from naïve animals are not (Sun et al., 2006; White et al., 2005b).
Moreover, CCR2 knockout mice do not develop neuropathic pain following spared nerve injury
(Abbadie et al., 2003), suggesting that upregulation of CCR2 is a crucial step in the generation
and/or maintenance of neuropathic pain. However, the transcriptional regulation of CCR2
receptors in DRG neurons has not been examined. Consequently, we wished to define the
signaling pathway responsible for the upregulation of these receptors in DRG neurons. In
addition to its diverse roles in the development and function of the immune system, it has
recently been shown that the nuclear factor of activated T-cells (NFAT) family of transcription
factors can play an important role in mediating long-term changes in neuronal excitability
(Graef et al., 1999). NFAT cannot normally enter the nucleus until it is dephosphorylated, but
can be activated by a Ca2+-dependent phophatase calcineurin (CN). Thus, an increase in
[Ca2+]i turns on the transcription of NFAT-dependent genes and this is believed to link transient
neuronal excitation to a long-lasting transcriptional activation (Graef et al., 1999; Zanzouri et
al., 2006).
Here we report that CCR2 is a target gene of the NFAT pathway in DRG neurons. We
demonstrate that there is a functional and conserved NFAT binding element in the promoter
region of the CCR2 gene. Activation of the NFAT pathway in DRG neurons and the DRG
neuronal cell line F11 increased the CCR2 promoter activity and initiated CCR2 transcription.
These data suggest that repetitive excitation of DRG neurons under pathological circumstances
might turn on activity-dependent transcription of CCR2 via NFAT signaling. Hence,
antagonism of the NFAT pathway may be a novel point for therapeutic intervention in treating
neuropathic pain.
Results
1. The structure of the mouse CCR2 gene
We examined the genomic organization of the mouse CCR2 gene. It is composed of three exons
with the entire protein coding region residing in the third exon (Fig 1A). The length of the 5’-
untranslated region (5’-UTR) varies among the reported mRNA sequences (Fig 1A). The
expected length of the first exon deduced from the longest reported sequence (AK046579) was
258 nt (Fig 1A). In order to see if this represents the transcription initiation site, we performed
a primer extension experiment with a primer selected from 61 nt downstream of the putative
initiation site (Fig 1B). RNA isolated from a mouse monocytic cell line WEHI265.1, from
which the first mouse CCR2 cDNA was cloned, was used (Kurihara and Bravo, 1996). A
specific band of the expected size was generated indicating that the transcription initiation site
lies around the expected region. To confirm this, RT-PCR was performed using a combination
of a reverse primer located in exon 3 and a forward primer located in exon 1 or in exon 2. As
expected, specific bands were only generated from the cDNA of WEHI265.1 cells but not from
F11 cells, a DRG neuronal cell line, using both combinations of primer sets (Kurihara and
Bravo, 1996) (Fig 1C). However, a distinct band that was around 100 bp shorter than the
expected size was also generated when the forward primer in exon 1 was used (Fig 1C: left
diagrams). The two bands were cloned and their sequence identities were verified. It was found
that there is a complete set of splice donor and acceptor sites within the exon 1, and the both
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mRNA species with the complete exon 1 and deleted exon 1 co-exist in WEHI265.1 cells (Fig
1D).
2. Cell type-specific activity of the CCR2 promoter
CCR2 is normally expressed by several cell types of the immune system including monocytes,
B-cells, activated T-cells, NK cells, and immature dendritic cells. On the other hand, under
normal conditions, DRG neurons do not express CCR2 receptors. However, CCR2 expression
can be upregulated in DRG neurons under pathological conditions. Accordingly, the DRG
neuronal cell line F11 did not express detectable levels of CCR2 mRNA, although this mRNA
was highly expressed by WEHI265.1 cells (Fig 1C and Fig 2A: left panels). The normal
expression of CCR2 mRNA in WEHI265.1 was due to active ongoing transcription since the
half-life of CCR2 mRNA in these cells was very short (Fig 2A: right panels). In order to define
the minimal promoter region responsible for cell type-specific CCR2 expression, a 1 kb
fragment upstream of the transcription initiation site was cloned into a luciferase reporter
vector, and the relative promoter activity was examined in these two cell lines. The activity of
the CCR2 promoter recapitulated the transcriptional activity and it was maintained even with
a 0.5 kb proximal fragment, suggesting that important regulatory cis-elements lie in the
relatively short fragment of the promoter (Fig 2B).
3. A functional NFAT binding element in the CCR2 promoter
In order to define signaling pathways whose activation might lead to the upregulation of
neuronal CCR2 receptors, putative transcription binding elements in the shorter fragment of
the CCR2 promoter were sought using standard programs (MatInspector v6.0, Genomatix
Software GmbH; MacVector, Accelrys). Among several sites, we located an NFAT binding
element conserved between human and mouse in the proximity of the transcription initiation
site (Fig 3A). To examine if this NFAT site is functional, we first performed an electrophoretic
mobility shift assay (EMSA) using nuclear extracts from WEHI265.1 cells. A specific binding
activity was observed (Fig 3B: filled arrowheads), which could be competed for by unlabeled
self-competitors but not by mutated competitors (GGAAAA → GGTTTT). The presence of
NFAT in these binding complexes was confirmed by ‘supershift’ assays. The formation of
specific binding complexes (Fig 3B: filled arrowheads) but not nonspecific ones (Fig 3B: empty
arrowheads) was inhibited by the addition of a pan-specific antibody to NFATc (which
recognizes NFATc1 to c4) but not by an isotype-matched control antibody. Next, we co-
transfected the CCR2 promoter with a constitutively active form of calcineurin A (a catalytic
subunit) (caCnA) to examine if the CCR2 promoter could be activated by the NFAT pathway.
CCR2 promoter activity was increased by caCnA, and this was blocked by a point mutation
in the NFAT binding sequence, indicating that the NFAT site in the CCR2 promoter is
functional (Fig 3C).
4. Involvement of the NFAT pathway in excitation-transcription coupling in DRG neurons
We used the DRG neuronal cell line F11 as a model for DRG neurons. F11 cells retain several
features of mature sensory neurons including the expression of voltage-sensitive Ca2+ channels
(VSCCs) and Substance P-like peptides (Francel et al., 1987), opioid receptors (Fan et al.,
1992), and transient receptor potential (TRP) channels (Jahnel et al., 2003). They also express
mRNA for calcitonin gene-related peptide (CGRP) and preprotachykinin (PPT; a precursor for
Substance P) (supplementary figure 1). We sought to examine if NFAT activation in DRG
neurons or F11 cells leads to upregulation of CCR2. First, we examined whether DRG neurons
and F11 cells express components of the NFAT pathway by RT-PCR. CnA and all isoforms
of NFAT were expressed in both DRG and F11 neurons (Fig 4A). Then, we asked whether
NFAT activation increases CCR2 promoter activity in F11 cells. F11 cells transfected with a
CCR2 promoter-luciferase construct were treated with the Ca2+ ionophore ionomycin (IM).
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IM treatment increased CCR2 promoter activity which was blocked by a CN inhibitor
cyclosporin A (CsA), indicating that the IM-mediated increase in CCR2 promoter activity was
due to NFAT activation (Fig 4B). Next, we examined if IM treatment could also increase CCR2
mRNA. IM treatment increased CCR2 mRNA (Fig 5A), and this was due to de novo synthesis
because the increase was completely blocked by the transcriptional inhibitor actinomycin D
(ActD). Moreover, it was mediated by activation of the NFAT pathway since it was inhibited
by CsA (Fig 5A). We reasoned that if the NFAT pathway is involved in the inducible regulation
of CCR2 gene expression, it may also participate in the normal constitutive cell type-specific
expression of CCR2. Accordingly, CCR2 mRNA levels were significantly decreased in
WEHI265.1 by FK506 or CsA.
Next, we asked if activation of NFAT could lead to the CCR2 upregulation in DRG neurons.
We developed a semi-acute DRG culture system to measure mRNA selectively from neurons
while minimizing contamination from non-neuronal cells (supplementary figure 2A).
Dissociated DRG cells were allowed to attach on an uncoated tissue culture dish for several
hours and then neurons were depolarized using a medium containing high concentration of
potassium (high K). Twenty four hours later, neurons which are loosely attached to dishes were
dislodged by gentle pipetting, total RNA was isolated, and RT-PCR was performed to measure
CCR2 mRNA. Neurons incubated in high K media had an elevated level of basal [Ca2+]i due
to activation of voltage-dependent Ca2+ channels (supplementary figure 2B). In the
unstimulated control group, where neurons were incubated in a medium containing a low
concentration of potassium while overall osmorality was maintained, CCR2 mRNA was
undetectable (Fig 6A). However, high K stimulation increased CCR2 mRNA which was
completely blocked by CsA/FK506, indicating that a depolarization-induced increase in CCR2
mRNA was mediated by activation of the NFAT pathway (Fig 6A and B).
Expression of several other chemokine receptors has also been closely associated with the
genesis of neuropathic pain (Bhangoo et al., 2006; Bhangoo et al., 2007). We therefore
examined whether additional chemokine receptors are targets of NFAT activation in DRG
neurons (Fig 6B). Among several chemokine receptors we examined (CCR1, CCR2, CCR5,
CXCR4 and CX3CR1), expression of CCR2 and CCR5 was induced by high K depolarization
in a CN inhibitor-sensitive manner (Fig 6B), suggesting that a group of chemokine receptor
genes could be induced synchronously using the same mechanism. CXCR4 expression,
however, was increased by CN inhibitors indicating that the same pathway might have opposite
effects on different genes. Expression of CCR1 and CX3CR1 remained unchanged. Overall,
these data suggest that the transcription of different groups of chemokine receptors is
differentially regulated at the transcriptional level in DRG neurons.
Discussion
Sustained pain hypersensitivity and neuronal hyperexcitability associated with neuropathic
pain is believed to result from long-term changes in gene expression in DRG and central dorsal
horn neurons. Many genes have been identified whose expression changes in association with
the development of neuropathic pain using several animal models, although the molecular
mechanisms responsible for such changes are largely unknown (Mogil et al., 2000). In
particular, the CCR2 chemokine receptor appears to play an important role in the genesis of
neuronal hyperexcitability in states of chronic pain (Abbadie et al., 2003; White et al.,
2005a; White et al., 2005b). This receptor is not expressed by DRG neurons under normal
circumstances but its expression is induced under pathological conditions. Accordingly, CCR2
expression was undetectable in cultured DRG neurons or F11 DRG neuronal cells. By
examining the promoter sequence of CCR2, we found that its expression in sensory neurons
can be induced by activation of the NFAT pathway.
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Transcriptional regulation of chemokine receptors in neurons has not been extensively studied,
since most research on this topic has been focused on immune cells. Previous reports using
immune cells have suggested that tissue specific expression of CCR2 was attributable to
differential Oct1 and C/EBP activities (Yamamoto et al., 1999). In the mouse promoter, Oct1
and C/EBP binding sites are also conserved. In accordance with this, we have observed that
co-transfection of C/EBPβ could also activate the CCR2 promoter, suggesting that multiple
transcriptional pathways may regulate CCR2 gene expression under different circumstances
(Jung and Miller, unpublished data). In addition to these transcription factors, constitutive
activity of NFAT signaling may also contribute to tissue specific expression, since inhibition
of the NFAT pathway by FK506 and CsA decreased constitutive levels of CCR2 mRNA in
WEHI265.1 monocyte cells (Fig 5B).
NFAT is a particularly pertinent candidate pathway for regulating activation of genes
responsible for neuropathic pain, because it can be activated by neuronal depolarization in a
Ca2+-dependent manner (Graef et al., 1999). It was recently shown that repetitive action
potentials in sympathetic neurons resulted in nuclear translocation of NFAT (Hernandez-
Ochoa et al., 2007). Since the ectopic discharge of action potentials in DRG neurons is a typical
feature of neuropathic pain (Basbaum and Woolf, 1999), tonic excitation of DRG neurons
under pathological conditions might induce the activity and Ca2+-dependent transcription of
NFAT target genes, including CCR2 receptors. Because CCR2 signaling in DRG neurons is
itself excitatory (Sun et al., 2006; White et al., 2005b), the net effect would be amplification
of hyperexcitability and pain. It is interesting to note that other forms of chemokine signaling
are also upregulated in the DRG in association with neuropathic pain including CCR5 and
CXCR4 receptors and their ligands (Bhangoo et al., 2006; Bhangoo et al., 2007). As we have
observed (Fig 6B), transcription of several chemokine receptor genes in DRG neurons appears
to involve diverse signaling pathways. For example, whereas upregulation of CCR2 and CCR5
in response to depolarization appears to proceed in an NFAT-dependent manner, CXCR4 was
upregulated by inhibition of the NFAT pathway. As the promoters for CCR2 and these other
chemokine receptors contain binding sites for multiple transcription factors it is likely that they
can be regulated by different signaling pathways under different circumstances- in addition to
depolarization. For example, chemokine receptor upregulation in response to inflammatory
cytokines such as TNF-α may also play a role in reshaping the gene expression profile of DRG
neurons in states of pain hypersensitivity and may function through pathways in addition to
NFAT (White et al., 2005a). Interestingly, we have demonstrated that in ganglia from animals
exhibiting nociceptive pain behavior, both CCR2 and its ligand MCP-1/CCL2 are upregulated
by the same neurons (Jung et al., in revision). As we have shown here CCR2 can be upregulated
by depolarization in a Ca2+/NFAT-dependent manner, but this is not the case for MCP-1
upregulation which does not respond to these stimuli. On the other hand MCP-1 can be
upregulated in a TNF-α/NF-kB-dependent manner (Supplementary figure 3). Thus, the entire
panoply of important gene transcriptional changes occurring in the DRG neurons in association
with states of chronic pain presumably result from a spectrum of transcriptional events.
It is known that NFAT-mediated transcription plays a role in neuronal development and
synaptic plasticity. With respect to DRG neurons in particular, Thayer and colleagues reported
that bradykinin, a pronociceptive peptide secreted from the site of injury, activates NFAT
signaling in DRG neurons resulting in NFAT-dependent transcription of COX2 (Jackson et
al., 2007). Seybold and colleagues reported that NGF and BDNF, pronociceptive
neurotrophins, also activate NFAT-dependent transcription (Groth et al., 2007). It is likely that
the NFAT pathway might not only be activated in the development phase of neuropathic pain
as a result of the action of multiple proinflammatory molecules, but also in the maintenance
phase where activity and Ca2+-dependent transcription takes place. Activation of diverse
transcriptional pathways, including NFAT might turn on the transcription of a cohort of genes
responsible for sustained hyperexcitability of DRG neurons in neuropathic pain. Therefore,
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the NFAT pathway may represent a novel point for therapeutic intervention in the treatment
of neuropathic pain. Because inhibition of transcriptional pathways such as NFAT may regulate
expression of several target genes, its inhibition may be more efficacious than individual
receptor antagonists in long-term reversal of chronic pain hypersensitivity.
Experimental Methods
Plasmid constructions and materials
The fragments of 5’-flanking region of CCR2 was amplified from mouse genomic DNA (from
a CD-1 mouse) by polymerase chain reaction (PCR) and cloned into pGL3-Basic (Promega).
A point mutation in the NFAT binding site was introduced using QuickChange site-directed
mutagenesis kit (Stratagene). The constitutively active calcineurin A construct (caCnA) was a
kind gift from Dr. Neil A. Clipstone (Loyola University Chicago, Maywood, IL) (Clipstone et
al., 1994). All PCR products were cloned into pCR2.1 vector (Invitrogen) and sequence
identities were confirmed by dideoxy-sequencing methods. Primers used in cloning are listed
in Table 1.
Cell culture
F11 rat DRG neuron X mouse neuroblastoma hybrid cells were grown in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 0.5%
penicillin-streptomycin (P/S) at 37°C under 5% CO2. WEHI265.1 mouse monocytic cells were
grown in the same condition except that the medium was further supplemented with 0.05 mM
2-mercaptoethanol. DRG neurons were isolated as described (Oh et al., 2001).
Northern blot analysis
Total RNA was extracted with Trizol reagent (Life Technologies). RNA was dissolved in
deionized water and denatured in 50% formamide, 6.2% formaldehyde, 20mM MOPS (3-[N-
morpholino]propanesulfonic acid), 5 mM sodium acetate, and 1 mM EDTA at 60 °C for 5 min.
Electrophoresis was performed at 100V for 1.5 hr in a submarine 1.2% formalehyde agarose
gel. RNA was transferred to Nytran filter (Amersham) for 18 hr by capillary transfer. CCR2
and GAPDH probes labeled with 32P-dCTP (Amersham) were prepared by random labeling
of mouse CCR2 cDNA 397 bp fragment and mouse GAPDH cDNA 800 bp fragment cloned
into pGEM-Teasy (Promega). Hybridization procedures and rehybridization with GAPDH
cDNA were performed using ExpressHyb hybridization solution (BD biosciences) according
to the manufacturer’s instructions. Primers used are listed in Table 1.
Reverse transcription-PCR (RT-PCR)
RNA samples (1 µg) were applied to the reverse transcription (RT) reaction containing 100 U
of Superscript II, 0.5 µg of oligo(dT) primers, 20 U of RNase inhibitor, and 1 mM dNTPs in
a buffer supplied by the manufacturer (Invitrogen). The RT reaction was carried out at 42°C
for 50 min followed by inactivation at 70°C for 15 min, after which RNase H was added and
the reaction mixture was incubated at 37°C for 30 min. Subsequently, 1/50 of reaction product
was added to 20 µl PCR reaction mixture containing 2.5 U of Taq DNA polymerase (Qiagen)
in a buffer supplied by the manufacturer. Thirty-two to forty-two cycles of PCR amplification
were carried out with the condition of denaturation at 95°C from 1 min, primer annealing at
55–60°C for 1 min, and primer extension at 72°C for 40 sec. Five µl aliquots of PCR products
were electrophoresed on 1.2 – 2.0 % agarose gel in Tris-acetate-EDTA buffer, stained with
ethidium bromide, and photographed under UV illumination. For quantitative PCR, real-time
PCR was performed using Taqman probe-based chemistry on a sequence detector (7900HT,
Applied Biosystems). Taqman gene expression assays containing two primers and one Taqman
probe for each gene were purchased from Applied Biosystems (listed in Table 1). The most
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assays (CCR2, CCR5, CXCR4, and CX3CR1) were designed to span an exon-exon boundary
to exclude false positive amplification of contaminated genomic DNA. Also, experiments with
the RTase-negative controls confirmed negligible levels of genomic DNA contamination in
cDNA samples (ΔCt ≈ 10). Relative quantification analyses were performed by a comparative
Ct method using GAPDH as an internal control.
Primer extension
Twenty pmole of primer (Table 1) was end-labeled with 32P-γ-dATP using T4 polynucleotide
kinase (PNK). One hundred fmole of primer was hybridized to 10 µg of total RNA isolated
from WEHI265.1 cells by incubating the sample at 58 °C for 20 min and slowly cooling to 10
°C, after which standard RT reaction mixture was added. Reaction products were resolved in
a 5% polyacrylamide gel in denaturing condition (7M urea and 1X Tris-borate-EDTA buffer).
Electrophoretic mobility shift assay (EMSA)
Four pmole of annealed oligonucleotides were labeled with 20 µCi of [α-32P] dCTP
(Amersham) using Klenow fragment (Promega). Labeled probes were diluted to 40 fmole/µl.
A total of 40 fmole of 32P-probe was incubated with 2–5 µg of nuclear extracts, which were
prepared using a commercial kit (Nuclear/Cytosol Fractionation Kit, BioVision, Mountain
View, CA), in gel shift assay buffer (20mM HEPES, pH 7.6, 0.1 mM KCl, 10% Glycerol, 0.1%
Nonidet P-40, 2 mM DTT) containing 0.5 µg of polydeoxyinosinic-deoxycytidylic acid in a
20-µl reaction. Binding reactions were performed on ice for 20 min and at 30 °C for 30 min.
The reaction mixture was run on a 4 % native polyacrylamide (37.5:1) gel in 0.5x TGE (25
mM Trizma base, 20 mM Glycine, 1 mM EDTA) to resolve protein-DNA complexes. For
competition assays, a 100-fold molar excess of unlabeled double-stranded competitor DNA
was added. For supershift assays, a pan-specific NFATc antibody which recognizes NFATc1
to c4 (sc-1149X) and an isotype-matched control antibody (Santa Cruz Biotechnology, Santa
Cruz, CA) were added at the beginning of the incubation at 30 °C. Oligomers used are listed
in Table 1.
Transient transfection and luciferase assay
Luciferase assay was performed to measure CCR2 promoter activities. DNA was transfected
using TranIT-LT1 (Mirus, WI) according to the manufacturer’s instructions. One hundred ng
of CCR2 promoter construct was co-transfected with 900 ng of transactivator construct or
empty vector along with 10 ng of pRL-TK, which served as an internal control. Renilla and
firefly luciferase assays were performed in 24–48 hr after the transfection using commercial
enzyme assay kits (Dual-Luciferase Reporter Assay System, Promega).
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Figure 1. The genomic organization of the mouse CCR2 gene
A) Reported mRNA species and their coverage on genomic DNA sequences (numbered boxes:
exons; lines between exons: introns; a black box: protein coding region). B) Primer extension
experiment. The location of the primer is denoted in the diagram on the left (W: WEHI265.1
monocytic cell line). C) RT-PCR experiments. Relative location of primers is denoted on the
upper diagram (arrow heads: primers). Two sets of primers were used: E1up/E3dn and E2up/
E3dn (left two and right two lanes, respectively). The structure of the PCR product is denoted
in the left and right diagrams (W: WEHI265.1 monocytic cell line; F: F11 DRG neuronal cell
line). D) The sequence of the exon 1 (E1). Exonic sequence is in upper cases and non-exonic
sequence in lower cases. An additional intronic sequence within the exon 1 is underlined. AG
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and GT consensus splice dinucleotides are in bold letters. An mRNA with this sequence spliced
out corresponds to the shorter band in the leftmost lane in C.
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Figure 2. Cloning of a functional CCR2 promoter
A) Cell type-specific CCR2 transcriptional activity. CCR2 was expressed by the WEHI265.1
(W) monocytic cell line but not by the F11 DRG neuronal cell line (F) under basal condition
(left panels). The half-life of CCR2 mRNA was examined in WEHI265.1 (right panels). After
the addition of a transcriptional inhibitor actinomycin D (ActD: 1 µg/ml), the CCR2 mRNA
level rapidly decreased. 28S rRNA was used as an internal control. B) Cell type specific CCR2
promoter activity. 1.0 kb and 0.5 kb fragments upstream of exon 1 (E1) were cloned into a
luciferase reporter vector (Luc). Promoter activity was high in WEHI265.1 cells but very low
in F11 cells (**p<0.01 and *p<0.05 between WEHI265.1 and F11, unpaired t-test).
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Figure 3. An NFAT element in the promoter
A) The NFAT binding element near the transcription initiation site is conserved (*) between
mouse and human (E1: exon 1). The core binding sequences are in bold. B) A specific NFAT
binding activity in the nuclear extract of WEHI265.1 cells (Co: cold competitors; S: self-
competitors; M: GGAAA → GGTTT mutated competitors; NE: nuclear extract from
WEH265.1 cells; a filled arrowhead: specific NFAT binding activity; an empty arrowhead:
binding activity that is not specific to the core NFAT sequence; Ab: antibody; IgG: an isotype-
matched control antibody; αNFATc: a pan-specific antibody to NFATc). C) The NFAT binding
element in the CCR2 promoter is functional. The CCR2 promoter (WT) or the promoter with
a point mutation in the NFAT binding site (Mut: GGAAA → GGTTT) was co-transfected with
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a constitutively active form of calcineurin A (caCnA) or an empty vector (***p<0.001; N.S.:
not significant, a post hoc Bonferroni’s multiple comparison test following one-way ANOVA).
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Figure 4. The components of the NFAT pathway in DRG neurons and F11 cells
A) Calcineurin A (CnA) and NFATc1-4 were expressed by cultured DRG neurons and F11
DRG neurons (RTase: reverse transcriptase). RTase-negative control reaction was performed
for each group. B) CCR2 promoter is activated by calcium ionophore ionomycin (IM: 1 µM)
in F11 DRG neurons in a calcineurin inhibitor cyclosporin A (CsA: 1 µM)-sensitive way
(**p<0.01, a post hoc Bonferroni’s multiple comparison test following one-way ANOVA).
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Figure 5. NFAT-dependent transcription of CCR2 in F11 and WEHI265.1 cells
A) NFAT-dependent de novo transcription of CCR2 in F11 DRG neurons. Ionomycin (IM: 1
µM) treatment induced CCR2 mRNA which was blocked by a transcriptional inhibitor
actinomycin D (ActD: 1 µg/ml). The induction was significantly inhibited by a calcineurin
inhibitor cyclosporin A (CsA: 1 µM). 28S rRNA was used as an internal control. B) NFAT-
dependent transcription contributes to cell type-specific CCR2 expression. Calcineurin
inhibitors CsA or FK506 (0.2 µM each) decreased baseline levels of CCR2 in WEHI265.1
monocytic cell line. GAPDH was used as an internal control.
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Figure 6. Depolarization-induced transcription of CCR2 in DRG neurons
A) NFAT-dependent transcription of CCR2 is induced in DRG neurons by depolarization.
Acutely isolated DRG neurons were depolarized by high external potassium (43K: 43 mM)
for 24 hr with or without calcineurin inhibitors (CsA/FK506: 0.2 µM each), which were added
30 min prior to depolarization. Control culture medium contained 3 mM of potassium (3K).
Osmorality of different media was identical. Total RNA was isolated from neurons (see
supplementary figure 1) and subjected to RT-PCR. B) Real-time quantitative RT-PCR was
used to quantify mRNA levels of different chemokine receptors in conditions described in A
(n=3–5 independent DRG cultures) (**p<0.01, *p<0.05 vs. 3K and ††p<0.01, †p<0.05 vs.
43K, a post hoc Bonferroni’s multiple comparison test following one-way ANOVA).
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Table 1
Primers for promoter cloning
1.0kb forward 5′-TTGGTACCTGCTTAGCTAGCATGTGT-3′
0.5kb forward 5′-TTGGTACCAACTCACACAAAGGGATC-3′
reverse 5′-AACTCGAGAATTTTGAAATCTTGCTTATGC-3′
mutNFAT forward 5′-GAAGAGAACAGAGAGTGGTTTAGCTATGAAAGACTTA-3′
mutNFAT reverse 5′-TAAGTCTTTCATAGCTAAACCACTCTCTGTTCTCTTC-3′
Primers for RT-PCR
CCR2 exon1 forward 5′-AATCCTGTAAAGACCTCAGCC-3′
CCR2 exon2 forward 5′-TGCAAAGACCAGAAGAGG-3′
CCR2 exon3 reverse 5′-CAGGATCCAAGCTCCAAT-3′
NFATc1 forward 5′-CAACGCCCTGACCACCGATAG-3′
NFATc1 reverse 5′-GGCTGCCTTCCGTCTCATAGT-3′
NFATc2 forward 5′-TGGCCCGCCACATCTACCCT-3′
NFATc2 reverse 5′-TGGTAGAAGGCGTGCGGCTT-3′
NFATc3 forward 5′-TGGATCTCAGTATCCTTTAA-3′
NFATc3 reverse 5′-CACACGAAATACAAGTCGGA-3′
NFATc4 forward 5′-CATTGGCACTGCAGATGAG-3′
NFATc4 reverse 5′-CGTAGCTCAATGTCTGAAT-3′
CnA forward 5′-CAGGGTGGTGAAAGCCGTTC-3′
CnA reverse 5′-GGATGTCCCCACAAACTGTG-3′
MCP-1 forward 5′-ATGCAGGTCCCTGTCATGCTT-3′
MCP-1 reverse 5′-GTTCACTGTCACACTGGTCA-3′
PPT-A forward 5′-TGCCAACGATGATCTAAATT-3′
PPT-A reverse 5′-CTTCTTTCGTAGTTCTGCAT-3′
CGRP forward 5′-AGATCCTGCAACACTGCCAC-3′
CGRP reverse 5′-CCACATTGGTGGGCACAAAGTTG-3′
GAPDH forward 5′-TTGACCTCAACTACATGG-3′
GAPDH reverse 5′-ATTGAGAGCAATGCCAGC-3′
Taqman gene expression assays for qRT-PCR
CCR1 Mm00438260_s1
CCR2 Mm00438270_m1
CCR5 m01216171_m1
CXCR4 m99999055_m1
CX3CR1 m00438354_m1
GAPDH m99999915_g1
Primers for the probes used in Northern blot
CCR2 3′UTR forward 5′-GCAAGAGGTCTCGGTTGGGTTG-3′
CCR2 3′UTR reverse 5′-TCCTCCTTCTCACTCAGTCCTG-3′
Primer for the primer extension
CCR2 exon1 reverse 5′-TCTACAGTTCTTCTTTTCCAGCCAGG-3′
Oligomers for EMSA
NFAT forward 5′-CTAGAGAGAGTGGAAAAGCTAT-3′
NFAT reverse 5′-CTAGATAGCTTTTCCACTCTCT-3′
Mutant NFAT forward 5′-CTAGAGAGAGTGGTTTAGCTAT-3′
Mutant NFAT reverse 5′-CTAGATAGCTAAACCACTCTCT-3′
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